Korean J Ophthalmol.  2010 Jun;24(3):155-158. 10.3341/kjo.2010.24.3.155.

The Effect of Intravitreal Bevacizumab in Patients with Acute Central Serous Chorioretinopathy

  • 1Department of Ophthalmology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea. jiwoneye@hallym.or.kr


To evaluate the effect of intravitreal bevacizumab injection (IVBI) in acute central serous chorioretinopathy (CSC) patients. METHODS: Patients with acute CSC received IVBI (1.25 mg/0.05 mL) or observation by randomization. Twelve eyes in each group completed 6 months of regular follow-up and were ultimately included in this study. Each patient was assessed using best corrected visual acuity measurements, fluorescein angiography, and optical coherence tomography at baseline and had regular follow-ups after treatment. RESULTS: All patients showed improvements in visual acuity and fluorescein angiographic leakage and had resolution of their neurosensory detachment following treatment. There were no significant differences in visual acuity, central retinal thickness, or remission duration between the IVBI group and the control group at baseline or after treatment (p>0.05). CONCLUSIONS: Intravitreal bevacizumab showed no positive effect in acute CSC patients compared to the observation group, and there were no adverse effects of treatment. Further investigation will be helpful to understand this therapy in patients with CSC.


Bevacizumab; Central serous chorioretinopathy; Randomized comparison; Therapeutics

MeSH Terms

Acute Disease
Antibodies, Monoclonal/*administration & dosage
Capillary Permeability/drug effects
Central Serous Chorioretinopathy/*drug therapy/physiopathology
Follow-Up Studies
Injections, Intraocular
Middle Aged
Treatment Failure
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
Visual Acuity/drug effects
Vitreous Body
Full Text Links
  • KJO
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr